HBV DNA Levels During Pregnancy in Chronic Hepatitis B
This study is currently recruiting participants.
Verified May 2012 by Chang Gung Memorial Hospital
Sponsor:
Chang Gung Memorial Hospital
Information provided by (Responsible Party):
Yi-Cheng Chen, Chang Gung Memorial Hospital
ClinicalTrials.gov Identifier:
NCT01610115
First received: May 30, 2012
Last updated: NA
Last verified: May 2012
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To elucidate the natural course of chronic hepatitis B by serial HBV DNA and alanine aminotransferase (ALT) levels during pregnancy
| Condition |
|---|
|
Hepatitis B Pregnancy |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Serial HBV DNA Levels During Pregnancy in Patients With Chronic Hepatitis B: a Prospective Observational Follow-up Study |
Resource links provided by NLM:
Further study details as provided by Chang Gung Memorial Hospital:
| Estimated Enrollment: | 100 |
| Study Start Date: | January 2012 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
This is a prospective observational follow-up study in a single center.
Number of patients: It is estimated to enroll 100 patients in Taiwan.
Population:
Female patients with pregnancy confirmed, at least 20 years of age diagnosed with chronic hepatitis B. The patients are able to communicate well, provide informed consent and willing to participate in the entire study.
Inclusion criteria:
Patients must meet all of the following criteria
- Documented chronic hepatitis B defined by clinical history compatible with chronic hepatitis B and detectable serum HBsAg
- Female 20 years of age with confirmed pregnancy
- Willing and able to comply with all the requirements in the observational followup study
- Willing and able to provide written informed consent to participate in the study
Exclusion criteria:
Patients will be excluded from the study for any of the following reasons:
- Concurrent infection with hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV)
- One or more known primary or secondary causes of liver disease other than hepatitis B (e.g., alcoholism, non-alcoholic steatohepatitis, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's disease, other congenital or metabolic conditions affecting the liver, congestive heart failure or other severe cardiopulmonary disease).
- Any other concurrent medical or psychosocial condition likely to preclude compliance with the schedule of evaluations in the protocol or likely to confound the efficacy or safety observations of the study.
- Enrolled or planning to enroll in another clinical trial of an investigational agent while participating in this study.
- Patients with antiviral therapy to chronic hepatitis B
Eligibility| Ages Eligible for Study: | 20 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
- Documented chronic hepatitis B defined by clinical history compatible with chronic hepatitis B and detectable serum HBsAg
- Female 20 years of age with confirmed pregnancy
Criteria
Inclusion Criteria:
- Documented chronic hepatitis B defined by clinical history compatible with chronic hepatitis B and detectable serum HBsAg
- Female 20 years of age with confirmed pregnancy
- Willing and able to comply with all the requirements in the observational follow-up study
- Willing and able to provide written informed consent to participate in the study
Exclusion Criteria:
- Concurrent infection with hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV)
- One or more known primary or secondary causes of liver disease other than hepatitis B (e.g., alcoholism, non-alcoholic steatohepatitis, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's disease, other congenital or metabolic conditions affecting the liver, congestive heart failure or other severe cardiopulmonary disease).
- Any other concurrent medical or psychosocial condition likely to preclude compliance with the schedule of evaluations in the protocol or likely to confound the efficacy or safety observations of the study.
- Enrolled or planning to enroll in another clinical trial of an investigational agent while participating in this study.
- Patients with antiviral therapy to chronic hepatitis B
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01610115
Contacts
| Contact: Mei-Hsia Ku | 886-3-3281200 ext 8114 | kuvicky1029@gmail.com |
| Contact: Yi-Cheng Chen | 886-3-3281200 ext 8107 | yichengliver@gmail.com |
Locations
| Taiwan | |
| Chang Gung Memorial Hospital | Recruiting |
| Taoyuan, Taiwan | |
| Contact: Mei-Hsia Ku 03281200 ext 8114 kuvicky1029@gmail.com | |
Sponsors and Collaborators
Chang Gung Memorial Hospital
Investigators
| Principal Investigator: | Yi-Cheng Chen, MD | Chang Gung Memorial Hospital |
More Information
No publications provided
| Responsible Party: | Yi-Cheng Chen, Chang Gung Memorial Hospital |
| ClinicalTrials.gov Identifier: | NCT01610115 History of Changes |
| Other Study ID Numbers: | HBV-P-01 |
| Study First Received: | May 30, 2012 |
| Last Updated: | May 30, 2012 |
| Health Authority: | Taiwan: Institutional Review Board |
Keywords provided by Chang Gung Memorial Hospital:
|
Pregnancy |
Additional relevant MeSH terms:
|
Hepatitis Hepatitis A Hepatitis B Hepatitis, Chronic Hepatitis B, Chronic Hepatitis, Viral, Human Liver Diseases |
Digestive System Diseases Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Hepadnaviridae Infections DNA Virus Infections |
ClinicalTrials.gov processed this record on May 21, 2013